ArticleCurrent microbiology2025
Loop 3 Repeats in Omp34 is a Promising Immunogen for Vaccine Development Against Acinetobacter baumannii Infections.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overuse of antibiotics has led to antibiotic-resistant Acinetobacter baumannii. This study evaluated the protective effect of a recombinant protein, derived from Omp34's loop 3 repeats, as a potential vaccine candidate against A. baumannii in a murine sepsis model. Recombinant Omp34 and L3 × 5 proteins were expressed in E. coli BL21 using the autoinduction method. The proteins were then purified and verified. To assess their protective efficacy, the proteins were injected into BALB/c mice, and the vaccine's effectiveness in both prevention and treatment stages was evaluated in a murine sepsis model against an infection caused by a clinical strain of A. baumannii. The study shows that recombinant proteins Omp34 and Omp34L3 × 5 have protective and immunogenic properties against A. baumannii. Using the immunogen loop 3, rather than the mature Omp34 protein, to stimulate the immune system yielded promising results. Omp34 offered superior protection, likely through B- and T-cell activation, while L3 × 5, though less protective, induced significant antibody production and recognized the clinical strain, warranting further research. The study highlights the potential of recombinant proteins Omp34 and Omp34L3 × 5 as vaccine candidates against A. baumannii. Omp34 provided stronger protection in mouse sepsis models, likely due to its activation of both B- and T-cell responses. While Omp34L3 × 5 was less protective, it still produced significant antibodies and recognized clinical strains. The results emphasize the need for further research into these proteins to develop vaccines or treatments against A. baumannii infections.
Indexed as
Identifiers
40389691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.